European Institute of Science Valuation
Is EURI B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of EURI B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de EURI B para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de EURI B para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EURI B?
Other financial metrics that can be useful for relative valuation.
What is EURI B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | kr1.40m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EURI B's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.5x | ||
QUIA QuiaPEG Pharmaceuticals Holding | 0.9x | n/a | kr3.8m |
DIABIO Diagonal Bio | 0.9x | n/a | kr3.0m |
SPAGO Spago Nanomedical | 10.8x | 50.6% | kr63.8m |
SPRINT Sprint Bioscience | 1.5x | 34.0% | kr75.1m |
EURI B European Institute of Science | 2.3x | n/a | kr1.4m |
Price-To-Sales vs. similares: EURI B es un buen valor basado en su Ratio Price-To-Sales (2.6x) comparado con la media de sus homólogos (3.6x).
Price to Earnings Ratio vs Industry
How does EURI B's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs. Industria: EURI B es un buen valor basado en su Ratio Price-To-Sales (4.6x) comparado con la media del sector Swedish Biotechs (11.2x).
Price to Sales Ratio vs Fair Ratio
What is EURI B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.3x |
Fair PS Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular EURI B's Price-To-Sales Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.